LCTX Lineage Cell Therapeutics
- 1.040
- -0.050-4.59%
- 1.060
- +0.020+1.92%
Lineage Cell Therapeutics News
Express News | Lineage Cell Therapeutics Inc: Prospectus Related to Offer of Common Shares From Time to Time Having Offering Price of up to $40.0 Mln Through Agent
Lineage Cell Therapeutics Q1 2024 Earnings: Aligns With EPS Projections Amidst Revenue Declines
Earnings Call Summary | Lineage Cell Therapeutics(LCTX.US) Q1 2024 Earnings Conference
The following is a summary of the Lineage Cell Therapeutics, Inc. (LCTX) Q1 2024 Earnings Call Transcript:Financial Performance:Lineage Cell Therapeutics reported Q1 2024 cash, cash equivalents and ma
Lineage Cell Therapeutics Q1 2024 GAAP EPS $(0.04), Inline, Sales $1.444M Beat $1.359M Estimate
Lineage Cell Therapeutics (AMEX:LCTX) reported quarterly losses of $(0.04) per share which met the analyst consensus estimate. This is a 33.33 percent decrease over losses of $(0.03) per share from th
Lineage Cell Therapeutics | 10-Q: Quarterly report
Express News | Lineage Cell Therapeutics: Cash, Cash Equivalents, & Marketable Securities as of March 31, 2024, Expected to Support Planned Operations Into Q3 2025.
Earnings Flash (LCTX) LINEAGE CELL THERAPEUTICS Reports Q1 Revenue $1.4M, Vs. Street Est of $1.36M
04:03 PM EDT, 05/09/2024 (MT Newswires) -- Earnings Flash (LCTX) LINEAGE CELL THERAPEUTICS Reports Q1 Revenue $1.4M, vs. Street Est of $1.36M
Lineage Cell Therapeutics 1Q Loss/Shr 4c >LCTX
Lineage Cell Therapeutics 1Q Loss/Shr 4c >LCTX
Press Release: Lineage Cell Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Update
Lineage Cell Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Update -- Established New Services Agreement with Genentech to Support Ongoing Development of th
Lineage Cell Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Update
PDF Version Established New Services Agreement with Genentech to Support Ongoing Development of the OpRegen Program Long-Term Visual Benefits from a Single Administration with OpRegen Reported
Buy Rating for Lineage Cell Therapeutics as OpRegen Shows Durable Benefits for GA Patients
Maintained Buy Rating for Lineage Cell Therapeutics on Robust Clinical Trial Results and Strong Partnership With Roche
Express News | Lineage Cell Therapeutics Shares Are Trading Are Higher After the Company Announced 24 Month Visual Acuity Results From Patients Enrolled in a Phase 1/2a Clinical Study of RG6501 in Patients With Geographic Atrophy Secondary to Age-related Macular...
Express News | Opregen® (Rg6501) Phase 1/2a Clinical Study 24-Month Visual Acuity Results Featured at 2024 Retinal Cell & Gene Therapy Innovation Summit
Express News | Lineage Cell Therapeutics to Report First Quarter 2024 Financial Results and Provide Business Update on May 9, 2024
Lineage Cell Therapeutics Board Chairman Passes Away
Lineage Cell Therapeutics: Saddened to Report the Passing of Long-Serving Chmn of the Bd of Directors, Alfred Kingsley >LCTX
Lineage Cell Therapeutics: Saddened to Report the Passing of Long-Serving Chmn of the Bd of Directors, Alfred Kingsley >LCTX
Express News | Lineage Cell Therapeutics Inc - Effective as of April 27 Michael H. Mulroy to Serve as Chairman of Board
Express News | Lineage Announces Changes to Board of Directors
Express News | Lineage Cell Therapeutics Inc May Offer And Sell Common Shares Of Up To $40M From Time To Time Through Or To B. Riley
Analysis
Price Target
No Data
